394 related articles for article (PubMed ID: 33421947)
1. A novel GLP-1 and FGF21 dual agonist has therapeutic potential for diabetes and non-alcoholic steatohepatitis.
Pan Q; Lin S; Li Y; Liu L; Li X; Gao X; Yan J; Gu B; Chen X; Li W; Tang X; Chen C; Guo L
EBioMedicine; 2021 Jan; 63():103202. PubMed ID: 33421947
[TBL] [Abstract][Full Text] [Related]
2. Design and pharmaceutical evaluation of bifunctional fusion protein of FGF21 and GLP-1 in the treatment of nonalcoholic steatohepatitis.
Ye X; Chen Y; Qi J; Zhu S; Wu Y; Xiong J; Hu F; Guo Z; Liang X
Eur J Pharmacol; 2023 Aug; 952():175811. PubMed ID: 37245859
[TBL] [Abstract][Full Text] [Related]
3. Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output.
Liu J; Yang K; Yang J; Xiao W; Le Y; Yu F; Gu L; Lang S; Tian Q; Jin T; Wei R; Hong T
EBioMedicine; 2019 Mar; 41():73-84. PubMed ID: 30827929
[TBL] [Abstract][Full Text] [Related]
4. A Novel Fc-FGF21 With Improved Resistance to Proteolysis, Increased Affinity Toward β-Klotho, and Enhanced Efficacy in Mice and Cynomolgus Monkeys.
Stanislaus S; Hecht R; Yie J; Hager T; Hall M; Spahr C; Wang W; Weiszmann J; Li Y; Deng L; Winters D; Smith S; Zhou L; Li Y; Véniant MM; Xu J
Endocrinology; 2017 May; 158(5):1314-1327. PubMed ID: 28324011
[TBL] [Abstract][Full Text] [Related]
5. Rationale-Based Engineering of a Potent Long-Acting FGF21 Analog for the Treatment of Type 2 Diabetes.
Hecht R; Li YS; Sun J; Belouski E; Hall M; Hager T; Yie J; Wang W; Winters D; Smith S; Spahr C; Tam LT; Shen Z; Stanislaus S; Chinookoswong N; Lau Y; Sickmier A; Michaels ML; Boone T; Véniant MM; Xu J
PLoS One; 2012; 7(11):e49345. PubMed ID: 23209571
[TBL] [Abstract][Full Text] [Related]
6. Stapled and
Chen X; Fu J; Zhou F; Yang Q; Wang J; Feng H; Jiang W; Jin L; Tang X; Jiang N; Yin J; Han J
J Med Chem; 2020 Nov; 63(21):12595-12613. PubMed ID: 33125843
[TBL] [Abstract][Full Text] [Related]
7. Albumin-binding domain extends half-life of glucagon-like peptide-1.
Tan H; Su W; Zhang W; Zhang J; Sattler M; Zou P
Eur J Pharmacol; 2021 Jan; 890():173650. PubMed ID: 33049303
[TBL] [Abstract][Full Text] [Related]
8. Hepatic Fibroblast Growth Factor 21 Is Involved in Mediating Functions of Liraglutide in Mice With Dietary Challenge.
Liu D; Pang J; Shao W; Gu J; Zeng Y; He HH; Ling W; Qian X; Jin T
Hepatology; 2021 Oct; 74(4):2154-2169. PubMed ID: 33851458
[TBL] [Abstract][Full Text] [Related]
9. [Preparation and the biological effect of fusion protein GLP-1-exendin-4/ IgG4(Fc) fusion protein as long acting GLP-1 receptor agonist].
Zheng YC
Yao Xue Xue Bao; 2015 Dec; 50(12):1668-72. PubMed ID: 27169293
[TBL] [Abstract][Full Text] [Related]
10. The effects of Fc fusion protein glucagon-like peptide-1 and glucagon dual receptor agonist with different receptor selectivity in vivo studies.
Jiang P; Zeng Y; Yang W; Li L; Zhou L; Xiao L; Li Y; Gu B; Li X; Li J; Li W; Guo L
Biomed Pharmacother; 2024 May; 174():116485. PubMed ID: 38518602
[TBL] [Abstract][Full Text] [Related]
11. Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice.
Wismann P; Pedersen SL; Hansen G; Mannerstedt K; Pedersen PJ; Jeppesen PB; Vrang N; Fosgerau K; Jelsing J
Physiol Behav; 2018 Aug; 192():72-81. PubMed ID: 29540315
[TBL] [Abstract][Full Text] [Related]
12. Cinchonine, a Potential Oral Small-Molecule Glucagon-Like Peptide-1 Receptor Agonist, Lowers Blood Glucose and Ameliorates Non-Alcoholic Steatohepatitis.
Xue H; Xing HJ; Wang B; Fu C; Zhang YS; Qiao X; Guo C; Zhang XL; Hu B; Zhao X; Deng LJ; Zhu XC; Zhang Y; Liu YF
Drug Des Devel Ther; 2023; 17():1417-1432. PubMed ID: 37197367
[TBL] [Abstract][Full Text] [Related]
13. Sustained release of a GLP-1 and FGF21 dual agonist from an injectable depot protects mice from obesity and hyperglycemia.
Gilroy CA; Capozzi ME; Varanko AK; Tong J; D'Alessio DA; Campbell JE; Chilkoti A
Sci Adv; 2020 Aug; 6(35):eaaz9890. PubMed ID: 32923621
[TBL] [Abstract][Full Text] [Related]
14. OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes.
Melander SA; Kayed A; Andreassen KV; Karsdal MA; Henriksen K
Eur J Pharmacol; 2024 Jan; 962():176215. PubMed ID: 38056618
[TBL] [Abstract][Full Text] [Related]
15. A GLP-1/GLP-2 receptor dual agonist to treat NASH: Targeting the gut-liver axis and microbiome.
Kim ER; Park JS; Kim JH; Oh JY; Oh IJ; Choi DH; Lee YS; Park IS; Kim S; Lee DH; Cheon JH; Bae JW; Lee M; Cho JW; An IB; Nam EJ; Yang SI; Lee MS; Bae SH; Lee YH
Hepatology; 2022 Jun; 75(6):1523-1538. PubMed ID: 34773257
[TBL] [Abstract][Full Text] [Related]
16. A long-acting FGF21 alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis partly through an FGF21-adiponectin-IL17A pathway.
Bao L; Yin J; Gao W; Wang Q; Yao W; Gao X
Br J Pharmacol; 2018 Aug; 175(16):3379-3393. PubMed ID: 29859019
[TBL] [Abstract][Full Text] [Related]
17. The Effects of Dual GLP-1/Glucagon Receptor Agonists with Different Receptor Selectivity in Mouse Models of Obesity and Nonalcoholic Steatohepatitis.
Kayed A; Melander SA; Khan S; Andreassen KV; Karsdal MA; Henriksen K
J Pharmacol Exp Ther; 2023 Mar; 384(3):406-416. PubMed ID: 36418115
[TBL] [Abstract][Full Text] [Related]
18. Balanced Coagonist of GLP-1 and Glucagon Receptors Corrects Dyslipidemia by Improving FGF21 Sensitivity in Hamster Model.
Patel V; Joharapurkar A; Kshirsagar S; Patel HM; Pandey D; Patel D; Sutariya B; Patel M; Bahekar R; Jain MR
Drug Res (Stuttg); 2017 Dec; 67(12):730-736. PubMed ID: 28898910
[TBL] [Abstract][Full Text] [Related]
19. Coagonist of GLP-1 and Glucagon Receptor Ameliorates Development of Non-Alcoholic Fatty Liver Disease.
Patel V; Joharapurkar A; Kshirsagar S; Sutariya B; Patel M; Patel H; Pandey D; Patel D; Ranvir R; Kadam S; Bahekar R; Jain M
Cardiovasc Hematol Agents Med Chem; 2018; 16(1):35-43. PubMed ID: 29357809
[TBL] [Abstract][Full Text] [Related]
20. The N-terminal alanine-extended GLP-1/IgG-Fc fusion protein confers resistance to DPP-IV and reduces serum glucose level in db/db mice.
Chung HS; Oh JY; Yoo SB; Lee SM; Cho HS
Regul Pept; 2011 Oct; 170(1-3):1-3. PubMed ID: 21621561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
